Key facts
- Spinogenix’s last known valuation is $335.0M (Mar 2026).
- It has raised $27.4M across 7 recorded rounds; the latest was Early Stage VC ($10.6M) in Nov 2025.
- Notable investors include United States Department of War, University of California, San Diego, Stead Impact Ventures and Foundation, U.S. Department of Health and Human Services.
- Spinogenix has filed 8 Form Ds with the SEC since 2017, most recently Jun 2024 ($2.8M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Spinogenix
Funding rounds
7 roundsAbout Spinogenix
Operator of a biopharmaceutical company intended to restore the brain connections and functions lost in brain injury and neurodegenerative diseases. The company offers drugs to reverse synapse loss, restoring connections lost to neurodegenerative diseases and other conditions involving the central nervous system, enabling patients to regenerate synapses through their direct modulation of synaptic proteins.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2016
- Employees
- 5
- Website
- spinogenix.com/
- Ownership
- Privately Held (backing)
Spinogenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Spinogenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Spinogenix in its N-PORT filings yet. We sweep new filings monthly.